| Project/Area Number |
15K09496
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKAO Shinji 金沢大学, 医学系, 教授 (70217660)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 再生不良性貧血 / CD109 / TGF‐β / PIGA遺伝子変異造血幹前駆細胞 / PIGA遺伝子変異 / GPIアンカー膜蛋白 / PNH型血球 / TGF-β / 造血抑制因子 |
|---|
| Outline of Final Research Achievements |
To determine whether a TGF-beta (b) co-receptor CD109 on hematopoietic stem progenitor cells (HSPCs) play a role in the preferential commitment of PIGA mutant HSPCs in patients with immune-mediated bone marrow failure (BMF), we established CD109-knock out (KO) TF-1, a GM-CSF-dependent myeloid leukemia cell line, using the CRIPR/Cas9 system, and compared the sensitivity of CD109KO TF-1 cells to TGF-b to that of wild-type (WT) TF-1 cells. The TGF-b treatment induced pSMAD2 in CD109KO TF-1 cells to a significantly lesser degree than in WT TF-1 cells. The proliferation of CD109KO TF-1 was inhibited by TGF-b also to a lesser degree than WT TF-1 cells. The results suggest that CD109, a glycosylphosphatidylinositol anchor protein, plays an enhancing role in the TGF-b signaling in HSPCs, and the lack of CD109 may make the HSPCs less sensitive to TGF-b, leading to the preferential commitment of the PIGA mutant HSPCs in immune-mediated BMF, in which TGF-b suppresses activation of WT HSPCs.
|
